Clinical trials: Covid19 Vaccine
Covid19, SARS-CoV Infection
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection
- Trial name
- NCT04668339
- Testing
- ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming
- Where
- 15 sites in United States, Singapore
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
SARS-CoV2 Infection
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.
- Trial name
- NCT05067946
- Testing
- GX-19N
- Volunteers
- healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above
This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to…
- Trial name
- NCT06374394
- Testing
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Social Acceptance, Social Anxiety
Social Acceptability of COVID-19 Vaccines in Pakistan
Social settings of Pakistan is unique in the sense that it is composed of multilingual, multicultural and different ethnicities. Also their believes and faiths are so unpredictable.
- Trial name
- NCT04727372
- Testing
- Questionnaire
- Where
- 4 sites in Pakistan
- Volunteers
- 986 people
- Sponsor
- Islamia University of Bahawalpur
Breast Cancer, Lung Cancer
To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment
This is a trial of prospective collection of serial blood samples after administration of COVID-19 vaccine in patients with cancer who are receiving active cancer treatment, planned to start therapy with 14 days of consent, or…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma (Skin)
- Trial name
- CANINE (NCT04821570)
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Kansas Medical Center
COVID-19
Conversation With Family Doctor to Increase COVID-19 Vaccine Uptake
The investigators will randomise individuals from family doctors' lists of patients that are at risk of severe Coronavirus Disease 2019 (COVID-19), and that are not registered as having taken the vaccine against the disease.
- Trial name
- NCT05207137
- Testing
- Telephone call about vaccination
- Where
- Norway
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
COVID-19
A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV_Beta in healthy participants.
- Trial name
- NCT05389319
- Testing
- Prime-2-CoV_Beta
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
COVID-19
Study of COVID-19 DNA Vaccine (AG0302-COVID19)
This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy adult volunteers.
- Trial name
- NCT04527081
- Testing
- AG0302-COVID19
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Covid19
Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study
Combinatorial phase I/II safety, tolerability and immunogenicity single center open-label clinical study of AKS-452 COVID-19 vaccination study
- Trial name
- ACT (NCT04681092)
- Testing
- AKS-452
- Where
- Netherlands
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345…
- Conditions
- SARS-CoV-2, Influenza, RSV
- Trial name
- NCT05585632
- Testing
- mRNA-1010, mRNA-1345, mRNA-1273.214
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Vaccines
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
The main objective of the study is to evaluate the effectiveness of the vaccine against covid-19, recommended by the national immunization program. This is a multicentric, observational, case-control study.
- Trial name
- NCT05621928
- Where
- Brazil
- Volunteers
- 3,920 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2)…
- Trial name
- NCT05310084
- Testing
- BNT162b2, Seasonal Inactivated Influenza Vaccine
- Where
- 26 sites in Australia, New Zealand
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Coronavirus, Covid19
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities
The primary objectives of this study are to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine CVnCoV, and to evaluate the humoral immune responses 14 days…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04860258
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium
- Volunteers
- 129 people
- Sponsor
- CureVac
Fever After Vaccination, Fever
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
This is a prospective, randomized, open-label clinical trial to evaluate the safety of COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential vaccination of COVID-19…
- Conditions
- Fever After Vaccination, Fever, Seizures Fever
- Trial name
- NCT06038617
- Testing
- mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
- Where
- 5 sites in United States
- Volunteers
- 347 people, healthy volunteers welcome
- Sponsor
- Duke University
SARS-CoV-2
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
The objective of the study is to demonstrate safety and immunogenicity of COVID-19 preventive DNA vaccine in elderly individuals.
- Trial name
- NCT04915989
- Testing
- GX-19N
- Where
- 2 sites in South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Coronavirus 2019, Healthcare Workers
Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine
Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic.
- Conditions
- Coronavirus 2019, Healthcare Workers, Vaccine
- Trial name
- NCT04843917
- Testing
- Immunoglobulin G detection
- Where
- Argentina
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
COVID-19, Pneumonia
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)
Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host inflammatory response and activation of coagulation pathways.
- Trial name
- ATTACC (NCT04372589)
- Testing
- Heparin
- Where
- 60 sites in United States, Brazil and 2 more
- Volunteers
- 1,200 people
- Sponsor
- University of Manitoba
COVID-19 Respiratory Infection, Covid19
COVID-19 Vaccine Hesitancy and Dental Faculty Staff Members in Egypt
Healthcare workers (HCWs) play a vital role in determining the success of vaccination programs. Patient acceptance and vaccination rely greatly on the utilization and attitude of HCWs towards the vaccine, their attitude also…
- Conditions
- COVID-19 Respiratory Infection, Covid19, Vaccine Refusal
- Trial name
- NCT05009043
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Mariam Ayman Amin Sharaf
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.